Pfizer names Ogilvy and Shire to handle PR for COX-2 drugs

Share this article:
Pfizer has named WPP Group's Ogilvy PR and Shire Health to handle
PR for its worldwide COX-2 franchise, including Celebrex, Bextra
and Dynastat. Ogilvy PR will handle U.S. communications for the drugs, while London-based Shire Health will handle the global business.
The move dislodges incumbent agency of record MS&L, along with
Weber Shandwick, which handled some global business on a project
basis. Neither agency participated in the pitch.
Pfizer's consolidation of the accounts predates Merck's withdrawal
of Vioxx in September, though the business is particularly critical as questions about the safety of COX-2 drugs now cloud the entire
category. Pfizer consolidated PR for its cardiovascular business into WPP in January.
"Our overall priority is to find better ways to reach people and persuade them to see their doctor about their pain," said Pfizer U.S. director of public relations Paul Ewing.
Share this article:

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.